{"filing":{"accession_number":"0001213900-26-081405","cik":"0001723980","ticker":"SXTC","company_name":"China SXT Pharmaceuticals, Inc.","form":"6-K","filing_date":"2026-07-24","report_date":"2026-07-24","primary_document":"ea0299108-6k_chinasxt.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1723980/000121390026081405/ea0299108-6k_chinasxt.htm"},"events":[{"id":20476,"run_id":18429,"accession_number":"0001213900-26-081405","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The press release announces a registered direct offering of 4.5 million units (each consisting of one Class A ordinary share and one common warrant) at $2.00 per unit, generating approximately $9 million in gross proceeds. This is a classic dilutive equity issuance to institutional investors under a shelf registration statement (Form F-3), materially diluting existing shareholders and raising capital through the sale of registered securities.","company_name":"China SXT Pharmaceuticals, Inc.","ticker":"SXTC","filing_date":"2026-07-24","form":"6-K","submitted_at":null,"items":[{"id":19843,"accession_number":"0001213900-26-081405","item_number":"EX-99.1","item_title":"ea029910801ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The press release announces a registered direct offering of 4.5 million units (each consisting of one Class A ordinary share and one common warrant) at $2.00 per unit, generating approximately $9 million in gross proceeds. This is a classic dilutive equity issuance to institutional investors under a shelf registration statement (Form F-3), materially diluting existing shareholders and raising capital through the sale of registered securities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:30:42.503058+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19843,"accession_number":"0001213900-26-081405","item_number":"EX-99.1","item_title":"ea029910801ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The press release announces a registered direct offering of 4.5 million units (each consisting of one Class A ordinary share and one common warrant) at $2.00 per unit, generating approximately $9 million in gross proceeds. This is a classic dilutive equity issuance to institutional investors under a shelf registration statement (Form F-3), materially diluting existing shareholders and raising capital through the sale of registered securities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:30:42.503058+00:00","company_name":"China SXT Pharmaceuticals, Inc.","ticker":"SXTC","filing_date":"2026-07-24"}]}